Oseltamivir

Journal of Postgraduate Medicine

Volumn 55, Issue 3, 2009, Pages 225-230

  Tullu, M S ^a  

^a KEM HOSPITAL   (India)

Author keywords

Fever; Flu; Influenza; Neuraminidase; Oseltamivir; Resistance; Virus

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; ZANAMIVIR;

ABDOMINAL CRAMP; ANTIVIRAL RESISTANCE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CREATININE CLEARANCE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MILK LEVEL; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; FATIGUE; GASTROINTESTINAL TRACT; HEADACHE; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYDROLYSIS; INFLUENZA; INFLUENZA VIRUS A H1N1; KIDNEY FAILURE; LIVER DISEASE; MENTAL CONCENTRATION; NAUSEA; PANDEMIC; PATIENT COMPLIANCE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STOMACH PAIN; TREATMENT DURATION; URINARY EXCRETION; VIRUS STRAIN; VOMITING;

DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR;

EID: 70449394215     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: 10.4103/0022-3859.57411     Document Type: Review

References (77)

1. Bardsley-Elliot A, Noble S. Oseltamivir. Drugs 1999;58:851-860
2. Fluvir (Oseltamivir Capsules 75 mg). Package insert. Himachal Pradesh, India: Hetero Drugs Limited.
3. McNicholl IR, McNicholl JJ. Neuraminidase inhibitors: Zanamivir and oseltamivir. Ann Pharmacother 2001;35:57-70.
4. Shigeta S. Oseltamivir (Guest Commentaries). Drugs 1999;58:861-862
5. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000;48:101-115
6. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, Sanasuttipun W, Shinde V, Kaewchana S, et al. Severe human influenza infections in Thailand: Oseltamivir treatment and risk factors for fatal outcome. PLoS One 2009;4:e6051.
7. Centers for Disease Control and Prevention (CDC). Update: Drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009;58:433-435
8. Fleming DM. Oseltamivir (Guest Commentaries). Drugs 1999;58:861.
9. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Lancet 2000;355: 1845-1850
10. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimircob Agents Chemother 1998;42:640-646
11. Tamiflu (Oseltamivir phosphate) capsules and oral suspension. Package insert. Roche Laboratories Inc. Gilead Sciences Inc, Foster City, California, 2008. Available from: http://www.rocheusa.com/ products/tamiflu/pi.pdf. [accessed on 2009 Aug 27].
12. Schirmer P, Holodniy M. Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opin Drug Saf 2009;8:357-371
13. Kamps BS, Hoffmann C. Oseltamivir (Drug profiles). In: Kamps BS, Hoffmann C, Preiser W, editors. Influenza report 2006. Paris: Flying Publisher; 2006. p. 194-207. Available from: http://www. influenzareport.com/ir/drugs/oselta.htm. [accessed on 2009 Aug 17].
14. Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, et al. The anti- influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 2002;30:13-19
15. Doucette KE, Aoki FY. Oseltamivir: A clinical and pharmacological perspective. Expert Opin Pharmacother 2001;2:1671-1683
16. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999;37:471-484
17. Snell P, Dave N, Wilson K, Rowell L, Weil A, Galitz L, et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol 2005;59:598-601.
18. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 2000;40:836-843
19. Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol 2003;59:411-415
20. Oo C, Barrett J, Hill G, Mann J, Dorr A, Dutkowski R, et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs 2001;3:229-236
21. Drug information: Oseltamivir. Medline plus. Available from: http:// www.nlm.nih.gov/medlineplus/druginfo/meds/a699040.html. [accessed on 2009 Aug 16].
22. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. JAMA 2000;283:1016-1024
23. Jefferson T. Influenza. BMJ Clin Evidence 2009;3:911.
24. Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51:123-129
25. Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, Duffy S, et al. Prescription of anti-influenza drugs for healthy adults: A systematic review and meta-analysis. Lancet Infect Dis 2009;9:537-545
26. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667-1672
27. Lin JT, Yu XZ, Cui DJ, Chen XY, Zhu JH, Wang YZ, et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin 2006;22:75-82.
28. Fluvir (Oseltamivir phosphate powder for oral suspension). Package Insert. India: Hetero Drugs Limited, Himachal Pradesh.
29. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: Cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003;139:321-329
30. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. JAMA 1999;282:1240-1246
31. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336-1343
32. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: Systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235.
33. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: A randomized controlled trial. JAMA 2001;285:748-754
34. Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, et al. Management of influenza in households: A prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004;189:440-449
35. Risebrough NA, Bowles SK, Simor AE, McGeer A, Oh PI. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities. J Am Geriatr Soc 2005;53:444-451
36. Khazeni N, Bravata DM, Holty JE, Uyeki TM, Stave CD, Gould MK. Safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 2009 in press.
37. Peters PH Jr, Gravenstein S, Norwood P, De Bock V, Van Couter A, Gibbens M, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001;49:1025-1031
38. Shijubo N, Yamada G, Takahashi M, Tokunoh T, Suzuki T, Abe S. Experience with oseltamivir in the control of nursing home influenza A outbreak. Intern Med 2002;41:366-370
39. Machado CM, Boas LS, Mendes AV, da Rocha IF, Sturaro D, Dulley FL, et al. Use of Oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 2004;34:111-114
40. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127-133
41. Johnston SL, Ferrero F, Garcia ML, Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 2005;24:225-232
42. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics 2009;124:170-178
43. Wallensten A, Oliver I, Lewis D, Harrison S. Compliance and side effects of prophylactic oseltamivir treatment in a school in South West England. Euro Surveill 2009;14:19285.
44. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007;44:197-202.
45. Huang YC, Li WC, Tsao KC, Huang CG, Chiu CH, Lin TY. Influenza- associated central nervous system dysfunction in Taiwanese children: Clinical characteristics and outcomes with and without administration of oseltamivir. Pediatr Infect Dis J 2009;28:647-648
46. Smith JR. Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009;63:596-605.
47. Centers for Disease Control and Prevention (CDC). Neurologic Complications Associated with Novel Influenza A (H1N1) Virus infection in children- Dallas, Texas, May 2009. MMWR Morb Mortal Wkly Rep 2009;58:773-778
48. Tanabe T, Hara K, Nakajima M, Shimakawa S, Tamai H. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection. Brain Develop 2009 in press.
49. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A (H1N1)v, May 2009: An internet-based cross-sectional survey. Euro Surveill 2009;14:19287.
50. Emergency dosing recommendations for treatment and prophylaxis of influenza in pediatric patients less than 1 year old. Available from: http:// www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ UCM153546.pdf. [accessed on 2009 Sep 3].
51. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 2009;181:55-58
52. Stohr K. Preventing and treating influenza: Neuraminidase inhibitors are clinically effective but have limitations. BMJ 2003;326:1223-1224
53. Burger RA, Billingsley JL, Huffman JH, Bailey KW, Kim CU, Sidwell RW. Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice. Immunopharmacology 2000;47:45-52.
54. Moscona A. Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 2005;353:2633-2636
55. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-2672
56. White NJ, Webster RG, Govorkova EA, Uyeki TM. What is the optimal therapy for patients with H5N1 influenza? PLoS Med 2009;6:e1000091.
57. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55:i5-i21.
58. Tumpey TM, Garcia-Sastre A, Mikulasova A, Taubenberger JK, Swayne DE, Palese P, et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci USA 2002;99:13849-13854
59. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, et al. Avian flu: Isolation of drug-resistant H5N1 virus. Nature 2005;437:1108.
60. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007;12:603-616
61. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AC. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A (H1N1) virus. JAMA 2009;301:1042-1046
62. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003;47:2264-2272
63. Enserink M. Newsfocus: A 'wimpy' flu strain mysteriously turns scary. Science 2009;323:1162-1163
64. Soderstrom H, Jarhult JD, Olsen B, Lindberg RH, Tanaka H, Fick J. Detection of the antiviral drug oseltamivir in aquatic environments. PLoS One 2009;4:e6064.
65. Shay DK, Ridenhour BJ. Can we "hedge" against the development of antiviral resistance among pandemic influenza viruses? PLoS Med 2009;6:e1000103.
66. Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: A plea for rational use. Clin Infect Dis 2009;48:1254-1256
67. Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009;48:389-396
68. Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J Infect 2009 in press.
69. Hall RJ, Peacey MP, Ralston JC, Bocacao J, Ziki M, Gunn W, et al. Pandemic influenza A(H1N1)v viruses currently circulating in New Zealand are sensitive to oseltamivir. Eur Surveill 2009;14:19282.
70. Besselaar TG, Naidoo D, Buys A, Gregory V, McAnerney J, Manamela JM, et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis 2008;14:1809-1810
71. Cheng PK, Leung TW, Ho EC, Leung PC, Ng AY, Lai MY, et al. Oseltamivir and amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis 2009;15:966-968
72. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, et al. Infections with oseltamivirresistant influenza A(H1N1) virus in the United States. JAMA 2009;301:1034-1041
73. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir- resistant influenza viruses A (H1N1), Norway, 2007-2008. Emerg Infect Dis 2009;15:155-162
74. Kawakami C, Obuchi M, Saikusa M, Noguchi Y, Ujike M, Odagiri T, et al. Isolation of Oseltamivir-resistant influenza A/ H1N1 virus of different origins in Yokohama city, Japan, during the 2007-2008 influenza season. Jpn J Infect Dis 2009;62:83-86
75. Meijer A, Lackenby A, Hungnes O, Lina B, van der Werf S, Schweiger B, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007- 08 season. Emerg Infect Dis 2009;15:552-560
76. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009;360:953-956
77. Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. JAMA 2009;301:1066-1069